The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...

Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable ...

Alzamend Neuro (ALZN) announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity, but additional data from the ELUCIDATE trial in various solid tumors ...

Chemomab Therapeutics (CMMB) announced results from the Open Label Extension portion of the Phase 2 SPRING trial assessing nebokitug as a ...

FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients. Ramat Gan, ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3KdThe European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...